Short Interest in NLS Pharmaceutics Ltd. (NASDAQ:NCEL) Declines By 94.8%

NLS Pharmaceutics Ltd. (NASDAQ:NCEL) was the recipient of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totaling 2,191 shares, a decrease of 94.8% from the December 15th total of 41,855 shares. Based on an average daily trading volume, of 42,567 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the shares of the company are short sold. Approximately 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 42,567 shares, the days-to-cover ratio is presently 0.1 days.

NLS Pharmaceutics Stock Performance

NASDAQ NCEL traded down $0.01 on Wednesday, reaching $2.46. 113,129 shares of the company were exchanged, compared to its average volume of 187,392. NLS Pharmaceutics has a fifty-two week low of $1.89 and a fifty-two week high of $33.70. The business’s fifty day moving average price is $3.12 and its 200 day moving average price is $14.28.

Analyst Upgrades and Downgrades

NCEL has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of NLS Pharmaceutics in a research report on Tuesday, October 14th. Wall Street Zen lowered NLS Pharmaceutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.